PICO Advisory Sub-Committee – Applications considered
- 1555.1 – Endoscopic sleeve gastroplasty for the treatment of patients with Class I and II obesity who have failed first line (lifestyle modification) and second line (pharmacotherapy) treatments
- 1657 – Rhenium-188 brachytherapy for non-melanoma skin cancer
- 1665 – Radiofrequency echographic multi spectrometry for bone density measurement and determination of osteopenia/osteoporosis
- 1675 – Whole Genome Sequencing for the diagnosis of mitochondrial disease
- 1680 – Genetic testing for childhood hearing impairment
- 1684 – Genetic testing for variants associated with haematological malignancies
- 1685 – Ventral rectopexy for the treatment of rectal prolapse and intussusception
- 1686 – 177Lutetium PSMA i&t for metastatic castrate resistant prostate cancer
- 1689 – Quantification of NT-proBNP in patients with systemic sclerosis, and in patients with diagnosed pulmonary arterial hypertension
- 1690 – Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell to treat refractory or relapsed multiple myeloma
- 1691 – PromarkerD testing in patients with type 2 diabetes to determine the risk of developing diabetic kidney disease